Key Insights

Highlights

Success Rate

94% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

2.7%

2 terminated out of 75 trials

Success Rate

93.8%

+7.2% vs benchmark

Late-Stage Pipeline

20%

15 trials in Phase 3/4

Results Transparency

20%

6 of 30 completed with results

Key Signals

6 with results94% success

Data Visualizations

Phase Distribution

62Total
Not Applicable (15)
P 1 (17)
P 2 (15)
P 3 (13)
P 4 (2)

Trial Status

Completed30
Recruiting19
Not Yet Recruiting14
Active Not Recruiting7
Enrolling By Invitation2
Terminated2

Trial Success Rate

93.8%

Benchmark: 86.5%

Based on 30 completed trials

Clinical Trials (75)

Showing 20 of 20 trials
NCT06943469Not ApplicableRecruitingPrimary

Effect of Partially Hydrolyzed Formula With Synbiotics on Skin Barrier Function

NCT07105488Phase 2Active Not RecruitingPrimary

A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis

NCT07298395Phase 2RecruitingPrimary

Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis

NCT07730788RecruitingPrimary

Reflectance Confocal Microscopy Evaluation of Skin Structure of Patients With Atopic Dermatitis Under Nemolizumab

NCT07693400Phase 2Active Not RecruitingPrimary

Topical Chinese Medicine and Exosome Mechanisms for Atopic Dermatitis

NCT07678645Phase 2Not Yet Recruiting

The Safety and Efficacy of Upadacitinib in Refractory Autoimmune Related Cholangitis and Atopic Dermatitis With Moderate to Severe Itching

NCT07659756RecruitingPrimary

Global Healthcare Study on Atopic Dermatitis

NCT07653386Not ApplicableCompleted

Clinical Trial of an Ointment in Patients With Mild and Moderate Atopic Dermatitis

NCT07544862RecruitingPrimary

A Study of Stapokibart Injection in Patients With Atopic Dermatitis (AD)

NCT05959083CompletedPrimary

Real World Study of Oral Upadacitinib Tablets to Assess Adverse Events and Change in Disease Activity in Adolescent and Adult Chinese Participants With Atopic Dermatitis

NCT07455578Phase 1Recruiting

Study of S-4321 in Participants With an Autoimmune or Immune-mediated Disease

NCT07205081Phase 1Active Not Recruiting

Safety, Tolerability and PK of ATTO-3712 in Healthy Volunteers and Patients With Atopic Dermatitis

NCT07146971Phase 1TerminatedPrimary

Clinical Evaluation of Skin Microbiome an Over-The-Counter (OTC) Drug for Atopic Dermatitis

NCT07453602Phase 1RecruitingPrimary

Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234

NCT07411755Phase 1RecruitingPrimary

A Phase 1 Clinical Study Comparing GS101 and Dupixent® After Subcutaneous Injection

NCT07503197Not ApplicableEnrolling By InvitationPrimary

A Study on the Efficacy of 2% Cholesterol Cream in Atopic Dermatitis

NCT07568665RecruitingPrimary

Evaluation by Confocal Reflectance Microscopy of the Skin Structure of Patients With Atopic Dermatitis Treated With Tralokinumab Biotherapy.

NCT06928246Phase 1RecruitingPrimary

The Impact of Botox on Neuroimmune Interactions in Atopic Dermatitis

NCT07550452Not ApplicableNot Yet RecruitingPrimary

Efficacy and Safety of Switching to Ivarmacitinib in Patients With Moderate-to-Severe Atopic Dermatitis With Inadequate Response to Interleukin-4 Receptor Alpha(IL-4Rα) Inhibitors: A Prospective, Multicenter, Real-World Study

NCT07329101Phase 1CompletedPrimary

Clinical Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VC005 in Adolescent Subjects With Mild to Moderate Atopic Dermatitis

Scroll to load more

Research Network

Activity Timeline